Select publications

Goy A et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2005;23(4):667-75. Abstract

Hagemeister FB. Mantle cell lymphoma: Non-myeloablative versus dose-intensive therapy. Leuk Lymphoma 2003;44(Suppl 3):69-75. Abstract

Hochster HS et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc ASCO 2004;Abstract 6502.

Kaminski MS et al. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352(5):441-9. Abstract

O’Connor OA et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23(4):676-84. Abstract

Shipley DL et al. Phase II trial of rituximab and short duration chemotherapy followed by 90Yibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial. Proc ASCO 2004;Abstract 6519.

Williams ME. ECOG 4402: Randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin’s lymphoma. Curr Hematol Rep 2004;3(6):395-6. No abstract available